Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

The Next Big Thing: An Obesity Initiative from the NIH

January 1, 1970 (Vol. , No. ) Zachary N. N. Russ Bioengineering graduate student UC Berkeley The phrase “fat and happy” couldn’t be going out of style faster. From the strangely coincident ads for weight loss and antidepressants on dating sites, to public weig

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

January 1, 1970 (Vol. , No. )

Zachary N. N. Russ Bioengineering graduate student UC Berkeley

The phrase “fat and happy” couldn’t be going out of style faster. From the strangely coincident ads for weight loss and antidepressants on dating sites, to public weight-control initiatives out of virtually every source (including celebrity chefs and the President of the United States), being overweight has never been so unpopular—or popular, since fully a third of American adults are considered obese.

Among others, the NIH Obesity Research Task Force (established in 2003) weighed in on obesity with their 2011 Strategic Plan, a follow-up to their 2004 Plan.

The five subsections of the report describe research into biological mechanisms, social correlations, group interventions, translation into policy, and measurement tools. The results of the research so far could be summed up as: “We have identified many biological pathways contributing to obesity, connected several social and cultural features to obesity, confirmed that coaching and weight loss help prevent obesity-related disorders, and have new information-gathering techniques and ways to better estimate the seriousness of the problem. We also have a very, very long way to go—back to the lab!”

It’s not for lack of effort. At least 3,800 obesity-related grants have been distributed since 2007, a purse of billions of dollars. Over 600 mention obesity in the title. And, while the connection is certainly a stretch for some of them, they really do cover every imaginable association.

From the molecular to the mundane, hard science and soft science are applied to every level of the problem.

From the influences of single proteins to the role of neighborhood planning and sidewalk connectivity, the task force jumps across disciplines to answer a few important question: Why did everyone start putting on weight? How does the body respond to being overweight? What can we do about it?”

This leads to interesting experiments. Some Amish will have their gut microflora reseeded with different strains for the advancement of science. Everything from meditation to lactation will be examined in the context of obesity.

This myriad-pronged approach demonstrates both a move to personalized medicine and a desperate need to do something about the problem, soon.

Been Here Before?

The obesity problem has several parallels: One example of a similar program in the NIH is the Office of AIDS Research (OAR), established in 1988. A look at their annual strategic plans shows a route much like that of the Obesity Task Force—the OAR weaves together basic research, therapeutics, clinical outcomes, and epidemiology.

As with HIV/AIDS, obesity drew in federal, state, and local resources to combat a rapidly spreading epidemic with both behavioral and medical interventions. This raises another similar epidemic: smoking and lung cancer.

For all three, even the initial interventions were similar: “Don’t do that,” where “that” refers to either unprotected sex and intravenous drugs, cigarettes, or greasy, sugary foods and a sedentary lifestyle. It took a full thirty years after the initial 1964 quit-smoking advisory to halve the per-capita tobacco consumption rate. Unfortunately, in spite of other initiatives, taxes, and interventions, there has not been much further progress.

If smoking and HIV are any indication, obesity and its associated illnesses will persist at a significantly steady-state level even after numerous public interventions. That steady state will remain until research comes up with a solution independent of behavior modification—like a cure, a vaccine, a way to clean lungs.

Perhaps, for obesity, that might be a gut symbiote that detects excessive blood sugar or some obesity marker and shuts down absorption of sugars and fats in response. If AIDS is any indication, it will be years before this research produces any major treatments, and the big cure is even further out.

Obesity is here to stay until someone comes up with a permanent, human nature-proof treatment for it. In the meantime, behavioral treatments may save an entire generation from eating itself to death. So, pass the celery!

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →